Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Thomas Powles(Queen Mary University of London), Şeyda Gündüz(Istinye University), Felipe Reyes-Cosmelli(Fundación Arturo López Pérez), Julia F. Markensohn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anja Lorch(Massachusetts Eye and Ear Infirmary), Chen Cai(University of Science and Technology of China), Graham Cohen(Life Groenkloof Hospital), Mackenzie Edmondson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yoshiaki Yamamoto(Yamaguchi University Hospital), Blanca Homet Moreno(Merck & Co., Inc., Rahway, NJ, USA (United States)), Evan Y. Yu(University of Washington), José F. Muñoz(Federal Highway Administration), Yen‐Hwa Chang(Taipei Veterans General Hospital), Carol E. Peña(Sepragen Corporation (United States)), Avivit Peer(Technion – Israel Institute of Technology), Abhishek Bavle(Baylor College of Medicine)
Cited by 35
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k